Advanced searches left 3/3

Metastatic Adenocarcinoma Lung - Europe PMC

Summarized by Plex Scholar
Last Updated: 19 May 2022

* If you want to update the article please login/register

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.

Erlotinib, a tyrosine kinase inhibitor, has been shown to prolong the lives of patients with epidermal growth factor receptor mutated non-small cell lung cancer patients. We wanted to investigate the effects of sarcopenia on erlotinib therapy and prognosis in patients with EGFR-mutated metastatic lung cancer. According to sarcopenia status, the patient characteristics, inflammation profiles, medical, and survival results of the erlotinib therapy were investigated. Patients with sarcopenia had a poor prognosis and had a shorter median progression-free life than patients without sarcopenia. In 34. 7% of patients treated with erlotinib, treatment-related toxicity occurred, but sarcopenia did not appear to have a significant effect on treatment-related toxicity. When erlotinib therapy is used in patients with sarcopenia and metastatic lung adenocarcinoma, the expected survival results could be poor. Using erlotinib, this research found that survival and medical outcomes could be more predicted by detecting sarcopenia in patients with lung cancer patients.

Source link: https://europepmc.org/article/MED/35575465


Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma.

Background Lung cancer is the most common cause of cancer death, partially due to its large heterogeneity. Methods In order to analyze the immunogenomic landscape of one primary and 19 synchronous metastatic tumors in a rare autopsy case involving genomic, epigenomic, and T cell heterogeneity in a rare autopsy study from a 32-year-old female never-smoker with left lung primary late-stage lung adenocarcinoma. A series of common T cell clonotypes were completely excluded from left-side thoracic tumors, revealing inconsistent T cell repertoire profiles between left-side and non-left-side thoracic tumors. Conclusions Our research reveals heterogeneous genomic and T cell profiles among synchronous metastases, as well as how restriction of particular T cell clonotypes within an individual may influence the chromosomic and epigenomic landscapes of synchronous lung metastases.

Source link: https://europepmc.org/article/MED/35546239


Radiomics predicts the EGFR mutation and subtypes in metastatic lung adenocarcinoma: a multi-center study

Purpose: To explore the use of multiparameter radiomics in the in-depth analysis of epidermal growth factor receptor mutation and subtypes in patients with primary lung cancer adenocarcinoma. Methods: Between Feb. 2016 and Oct. 2020, a primary cohort was conducted with 257 patients who pathologically confirmed spinal bone metastasis from the first center between February 2016 and October 2020. MRI imaging studies of patients underwent sagittal T1-weighted imaging and sagittal fat-suppressed T2-weight imaging. To create radiomics models for predicting the EGFR mutations and subtypes, machine learning algorithms were used with 5-fold cross-validation. T1W's RSs had higher results for predicting the EGFR mutation and subtypes of EGFR mutation and subtypes compared to T2FS' in terms of AUC, accuracy, and specificity, compared to T2FS'. The nomogramogram models incorporating RSs from a combination of the two MRI sequences and key clinical variables provided the highest prediction accuracy in the preparation, internal validation, and external validation.

Source link: https://europepmc.org/article/PPR/PPR489117


Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion.

According to 1-2% of non-small cell lung cancer patients, rearranged patients account for 1-2% of non-small cell lung cancer cases. Approximately ten fusion partners have been identified, while clinical research is currently gaining evidence of new ones and their therapeutic responses. We present a patient with stage IV NSCLC who underwent a dramatic but brief reaction to first line crizotinib and primary resistance to subsequent ceritinib. In a 53-year-old woman who complained of persistent cough, computed tomography revealed a pulmonary nodule. The tissue biopsy revealed a poorly differentiated adenocarcinoma staining negative for PD-L1 but a novel translocated promoter region, the ROS1 gene fusion, which was consistent. A rapid partial response after 1 month was elicited by the virus, but the condition stayed for another 2 months. The patient's symptoms of acute lung and brain cancers had risen after three months of continuing crizotinib therapy.

Source link: https://europepmc.org/article/MED/35574423


Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis?

By analyzing the data from 1342 patients in our institution, we hope to determine the effect of metastatectomy and prognostic factors in PDAC patients with isolated lung metastasis. Compared to patients who received only chemotherapy or supportive care, PDAC patients with isolated lung metastasis who underwent metastatectomy had improved survival when compared to those who received only chemotherapy or supportive care. According to our results, PDAC patients with isolated lung metastasis should be considered for multimodal therapy with chemotherapy and surgical therapy. After metastasis in PDAC patients with isolated lung metastasis, we investigated the effect of metastatectomy on survival. Patients with PDAC distant metastasis from January 2007 to December 2018, of whom 83 patients had isolated pulmonary metastasis, were analyzed by this retrospective analysis.

Source link: https://europepmc.org/article/MED/PMC9099489


Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis?

Metastatectomy results are lacking in the era of medically-based chemotherapy of pancreatic ductal adenocarcinoma with distant metastasis. After metastasis in PDAC patients with isolated lung metastasis, we investigated the effects of metastatectomy on survival. 83 patients had isolated pulmonary metastasis from January 2007 to December 2018, of whom 1342 patients were histologically diagnosed with PDAC with distant metastasis from January 2007 to December 2018. Metastatectomy with primary pancreatic lesions is recommended for PDAC patients with isolated lung metastasis.

Source link: https://europepmc.org/article/MED/35565195


Metachronous Adenocarcinoma of Lung in the setting of Metastatic Gastric Neuroendocrine Tumor: value of elucidating discordance on Dual Tracer PET/CT (18F-FDG and 68Ga-DOTATATE).

Dual tracer PET/CT exams have become an established strategy in the care of metastatic Neuroendocrine neoplasms and demonstrate the benefits of deciphering tumor characteristics by molecular PET data in patient care. This is a case-example of incidentally finding 18F-FDG avid metachronous lung carcinoma in a patient of metastatic well differentiated gastric NEN, wherein dual tracer PET/CT analysis revealed FDG avid but non-68Ga-DOTATATE avid lung opacity, according to the study.

Source link: https://europepmc.org/article/MED/35440472


Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma.

Background Guidelines in 2013 and 2014 suggested Epidermal Growth Factor Receptor testing for metastatic lung adenocarcinoma patients, but targeted therapies' effectiveness depends on the mutations. Methods We found 2362 patients with metastatic lung cancer adenocarcinoma from January 2013 to December 2015 using the SEER-Medicare database, which included 2362 patients at least 65 years old, recently diagnosed with metastatic lung adenocarcinoma. In terms of Medicare costs and patient out-of-pocket costs, we reviewed the benefits of both EGFR testing and targeted therapy. Conclusion This population-based study indicates that testing guidelines increased the use of EGFR testing, although a substantial number of patients receiving targeted therapy without testing was still out of place. Both Medicare and patients' costs were considerably higher than those required to perform clinical outcomes, showing that clinicians must adhere to testing protocols in order to improve clinical outcomes while still lowering the financial burden for both Medicare and patients.

Source link: https://europepmc.org/article/MED/35397521


Bevacizumab plus dacomitinib combination therapy for L858R-mutated metastatic lung adenocarcinoma: A report of two cases.

Previous randomized controlled trials have shown that dual inhibition of the epidermal growth factor receptor and vascular endothelial growth factor pathways for the treatment of EGFR-mutated, non-small cell lung cancer therapy is backed by previous controlled trials. The second case involves a 60-year-old woman who complained of low back pain and was found with right lower lung adenocarcinoma with bone metastasis and L858R mutation. The first patient's response was almost complete, and the second patient had a partial reaction after the combination therapy and no serious side effects.

Source link: https://europepmc.org/article/MED/35343086


Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.

Patients with heavily treated anaplastic lymphona kinase kinase-positive nonsmall cell lung cancer patients, who often have immune mechanisms to ALK tyrosine kinase inhibitors, are often limited to chemotherapy, which causes little clinical benefit and may cause severe toxicity. In a few tumor forms, a BReast CAncer gene 1/2 mutated patients, such as olaparib, are now approved to treat BReast CAncer gene 1/2 mutated patients. A trial and two case reports of an olaparib-containing treatment of epidermal growth factor receptor -positive or driver-negative NSCLC have been published. We discuss an example of a 27-year-old female nonsmoker diagnosed with ALK-rearranged metastatic lung adenocarcinoma. In ALK-positive, gBRCA-mutated metastatic NSCLC, this case is the first to show clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK-positive, gBRCA-mutated metastatic NSCLC, to the best of our knowledge. Our results in BRCA1/2-mutated NSCLC reinforces previous findings on PARP inhibition in EGFR-positive or driver-negative patients.

Source link: https://europepmc.org/article/MED/35324529

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions